Decoy Receptor 3 Overexpression and Immunologic Tolerance in Hepatocellular Carcinoma (HCC) Development

REFERENCES

• Migone T. S., Zhang J., Luo X., Zhuang L., et al. TL1A is a TNF-like ligand for DR3 and TR6/DcR3 and functions as a T cell costimulator. Immunity 2002; 16: 479–92
   PubMed Web of Science ®Google Scholar
• Hayashi S., Miura Y., Nishiyama T., et al. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum 2007; 56: 1067–1075
   PubMed Web of Science ®Google Scholar
• Pitti R. M., Marsters S. A., David A., et al. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998; 396: 699–703
   PubMed Web of Science ®Google Scholar
• Shen H. W., Wu Y. L., Peng S. Y., et al. Overexpression and genomic amplification of decoy receptor 3 in hepatocellular carcinoma and significance thereof. Zhonghua Yi Xue Za Zhi 2003; 83: 744–747
   PubMedGoogle Scholar
• Chang Y. C., Hsu T. L., Lin H. H., et al. Modulation of macrophage differentiation and activation by decoy receptor 3. J Leukoc Biol 2004; 75: 486–494
   PubMed Web of Science ®Google Scholar
• Tsui-Ling H., Ying-Yu W., Yung-Chi C., et al. Attenuation of Th1 Response in Decoy Receptor 3 Transgenic Mice. J Immunol, 2005; 175: 5135–5145
   PubMed Web of Science ®Google Scholar
• Tokumasa N., Suto A., Kagami S. I., et al. Expression of Tyk2 in dendritic cells is required for IL-12, IL-23, and IFN-gamma production and the induction of Th1 cell differentiation. Blood 2007
   PubMedGoogle Scholar
• Wortinger M. A., Foley J. W., et al. Fas ligand-induced murine pulmonary inammation is reduced by a stable decoy receptor 3 analogue. Immunol 2003; 110: 225–233
   PubMed Web of Science ®Google Scholar
• Suda T., Takahashi T., Golstein P., Nagata S. Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993; 75: 1169–1178
   PubMed Web of Science ®Google Scholar
• Manicassamy S., Sun Z. The critical role of protein kinase C-theta in Fas/Fas ligand-mediated apoptosis. J Immunol Jan 1, 2007; 178(1)312–319
   PubMed Web of Science ®Google Scholar
• Matute-Bello G., Liles W. C., Frevert C. W., et al. Blockade of the Fas/FasL system improves pneumococcal clearance from the lungs without preventing dissemination of bacteria to the spleen. J Infect Dis Feb 15, 2005; 191(4)596–606
   PubMed Web of Science ®Google Scholar
• Fecci P. E., Mitchell D. A., Whitesides J. F., et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 2006; 66: 3294–3302
   PubMed Web of Science ®Google Scholar
• Cesana G. C., DeRaffele G., Cohen S., et al. Characterization of CD4+CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 2006; 24: 1169–1177
   PubMed Web of Science ®Google Scholar
• Li X., Ye D. F., Xie X., Chen H. Z., Lu W. G. Increase of CD4+CD25+ regulatory T cell in the patients with ovarian carcinoma. Cancer Invest 2005; 23: 399–403
   PubMed Web of Science ®Google Scholar
• Curiel T. J., Coukos G., Zou L., et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942–949
   PubMed Web of Science ®Google Scholar
• Wolf D., Wolf A. M., Rumpold H., et al. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer. Clin Cancer Res 2005; 11: 8226–8229
   PubMed Web of Science ®Google Scholar
• Marie J. C., Letterio J. J., Gavin M., Rudensky A. Y. TGF-beta1 maintains suppressor function and Foxp3 expression in CD4+CD25+ regulatory T cells. J Exp Med 2005; 201: 1061–1067
   PubMed Web of Science ®Google Scholar
• Watanabe N., Wang Y. H., Lee H. K., et al. Hassall's corpuscles instruct dendritic cells to induce CD4+CD25+ regulatory T cells in human thymus. Nature 2005; 436: 1181–1185
   PubMed Web of Science ®Google Scholar
• Chen W., Jin W., Hardegen N., et al. Conversion of peripheral CD4+CD25− naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875–1886
   PubMed Web of Science ®Google Scholar
• Peng Y., Laouar Y., Li M. O., Green E. A., Flavell R. A. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc Natl Acad Sci USA 2004; 101: 4572–4577
   PubMed Web of Science ®Google Scholar
• Hong J., Li N., Zhang X., Zheng B., Zhang J. Z. Induction of CD4+CD25+ regulatory T cells by copolymer-I through activation of transcription factor Foxp3. Proc Natl Acad Sci USA 2005; 102: 6449–6454
   PubMed Web of Science ®Google Scholar
• Khattri R., Cox T., Yasayko S. A., Ramsdell F. An essential role for scurfin in CD4+CD25+ T regulatory cells. Nat Immunol 2003; 4: 337–342
   PubMed Web of Science ®Google Scholar
• Hori S., Nomura T., Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 1057–1061
   PubMed Web of Science ®Google Scholar
• Yagi H., Nomura T., Nakamura K., et al. Crucial role of FOXP3 in the development and function of human CD25+CD4+ regulatory T cells. Int Immunol 2004; 16: 1643–1656
   PubMed Web of Science ®Google Scholar
• Cellular and molecular immunology, A. K. Abbas, A. H. Lichtman, J. S. Pober. WB Saunders Company, Philadelphia (PA) 1994; 315–346
   Google Scholar
• Valente G., Ozmen L., Novelli F., Geuna M., Palestro G., Forni G., Garotta G. Distribution of interferon- receptor in human tissues. Eur J Immunol 1992; 22: 2403
   PubMed Web of Science ®Google Scholar
• Farrar M. A., Schreiber R. D. The molecular cell biology of interferon- and its receptor. Annu Rev Immunol 1993; 11: 571
   PubMed Web of Science ®Google Scholar
• Langaas V., Shahzidi S., Johnsen J. I., Smedsrod B., Sveinbjornsson B. Interferon-modulates TRAIL-mediated apoptosis in human colon carcinoma cells. Anticancer Res 2001; 21: 3733
   PubMed Web of Science ®Google Scholar
• Mazzolini G., Narvaiza I., Martinez-Cruz L. A., Arina A., Barajas M., Galofre J. C., Qian C., Mato J. M., Prieto J., Melero I. Pancreatic cancer escape variants that evade immunogene therapy through loss of sensitivity to IFN–induced apoptosis. Gene Ther 2003; 10: 1067
   PubMed Web of Science ®Google Scholar
• Dighe A. S., Richards E., Old L. J., Schreiber R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN-γ receptors. Immunity 1994; 1: 447
   PubMed Web of Science ®Google Scholar
• Basham T. Y., Merigan T. C. Recombinant interferon-γ increases HLA-DR synthesis and expression. J Immunol 1983; 130: 1492
   PubMed Web of Science ®Google Scholar
• Houghton A. N., Thomson T. M., Gross D., Oettgen H. F., Old L. J. Surface antigens of melanoma and melanocytes: specificity of induction of Ia antigens by human γ-interferon. J Exp Med 1984; 160: 255
   PubMed Web of Science ®Google Scholar
• Brunda M. J., Rosenbaum D. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons. Cancer Res 1984; 44: 597
   Google Scholar
• Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., et al. Nat Med 2004; 10: 48–54
   PubMed Web of Science ®Google Scholar
• Sato T., McCue P., Masuoka K., Salwen S., Lattime E. C., Mastrangelo M. J., Berd D. Interleukin 10 production by human melanoma. Clin Cancer Res 1996; 2: 1383–1390
   PubMed Web of Science ®Google Scholar
• Patel K. B., Berd D., Mastrangelo M. J., Terai M., Sato T. Prognostic importance of interleukin-10 (IL-10) production by metastatic melanoma tissues from patients receiving autologous vaccine therapy. Proceedings ASCO 2002; 432
   Google Scholar
• Koli K. M., Arteaga C. L. Complex role of tumor cell transforming growth factor (TGF)-beta s on breast carcinoma progression. J. Mammary Gland Biol. Neoplasia 1996; 1: 373–380
   PubMed Web of Science ®Google Scholar
• Oh Y., Muller H. L., Ng L., Rosenfeld R. G. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 1995; 9: 13589–13592
   Google Scholar